BUZZ-Hims & Hers falls, set for tenth straight day of losses

Reuters02-13

** Shares of telehealth company Hims & Hers Health HIMS.N fall 4% to $16.01 in afternoon trading, on track for their tenth straight day of losses

** Last week, HIMS said it would launch a $49 compounded version of Novo Nordisk's Wegovy pill for weight loss, which was then withdrawn after scrutiny from the U.S. health regulator

** Co's shares fell further after Danish drugmaker Novo sued HIMS over patent infringement of semaglutide, the active ingredient in Wegovy

** Novo has sued several compounders for allegedly selling unsafe, falsely advertised Wegovy "knockoffs" that violate its trademark rights, but the Hims lawsuit is its first U.S. patent case against a compounder

** Up to last close, HIMS down 50% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611979236?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 02:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611979236","market":"us","top_or_hot":-1,"title":"BUZZ-Hims & Hers falls, set for tenth straight day of losses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Hims &amp; Hers falls, set for tenth straight day of losses</title></head><body><p>** Shares of telehealth company Hims &amp; Hers Health <span>HIMS.N</span> fall 4% to $16.01 in afternoon trading, on track for their tenth straight day of losses</p><p>** Last week, HIMS said it would <span>launch</span> a $49 compounded version of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy pill for weight loss, which was then <span>withdrawn</span> after <span>scrutiny</span> from the U.S. health regulator</p><p>** Co's shares fell further after Danish drugmaker Novo <span>sued</span> HIMS over patent infringement of semaglutide, the active ingredient in Wegovy</p><p>** Novo has sued several compounders for allegedly selling unsafe, falsely advertised Wegovy \"knockoffs\" that violate its trademark rights, but the Hims lawsuit is its first U.S. patent case against a compounder</p><p>** Up to last close, HIMS down 50% YTD</p><p>(Reporting by Christy Santhosh)</p><p>((Christy.Santhosh@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Hims & Hers falls, set for tenth straight day of losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Hims & Hers falls, set for tenth straight day of losses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-13 02:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Hims &amp; Hers falls, set for tenth straight day of losses</title></head><body><p>** Shares of telehealth company Hims &amp; Hers Health <span>HIMS.N</span> fall 4% to $16.01 in afternoon trading, on track for their tenth straight day of losses</p><p>** Last week, HIMS said it would <span>launch</span> a $49 compounded version of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy pill for weight loss, which was then <span>withdrawn</span> after <span>scrutiny</span> from the U.S. health regulator</p><p>** Co's shares fell further after Danish drugmaker Novo <span>sued</span> HIMS over patent infringement of semaglutide, the active ingredient in Wegovy</p><p>** Novo has sued several compounders for allegedly selling unsafe, falsely advertised Wegovy \"knockoffs\" that violate its trademark rights, but the Hims lawsuit is its first U.S. patent case against a compounder</p><p>** Up to last close, HIMS down 50% YTD</p><p>(Reporting by Christy Santhosh)</p><p>((Christy.Santhosh@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMZ","symbol_name":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL4N3Z824X:1","article_id":"2611979236","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611979236","pubTimestamp":1770920348,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Hims & Hers falls, set for tenth straight day of losses** Shares of telehealth company Hims & Hers Health HIMS.N fall 4% to $16.01 in afternoon trading, on track for their tenth straight day of losses** Last week, HIMS said it would launch a $49 compounded version of Novo Nordisk's Wegovy pill for weight loss, which was then withdrawn after scrutiny from the U.S. health regulator** Co's shares fell further after Danish drugmaker Novo sued HIMS over patent infringement of semaglutide, the active ingredient in Wegovy** Novo has sued several compounders for allegedly selling unsafe, falsely advertised Wegovy \"knockoffs\" that violate its trademark rights, but the Hims lawsuit is its first U.S. patent case against a compounder** Up to last close, HIMS down 50% YTD","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","HIMS":"Hims & Hers Health Inc.","BK4196":"保健护理服务","HIMY":"Defiance Leveraged Long + Income HIMS ETF","HMYY":"GraniteShares YieldBoost HIMS ETF"},"translate_title":"BUZZ-Hims&Hers下跌，连续第十天亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HMYY":0.6,"HIMY":0.6,"HIMZ":0.6,"HIMS":1.97},"content_text":"BUZZ-Hims & Hers falls, set for tenth straight day of losses** Shares of telehealth company Hims & Hers Health HIMS.N fall 4% to $16.01 in afternoon trading, on track for their tenth straight day of losses** Last week, HIMS said it would launch a $49 compounded version of Novo Nordisk's Wegovy pill for weight loss, which was then withdrawn after scrutiny from the U.S. health regulator** Co's shares fell further after Danish drugmaker Novo sued HIMS over patent infringement of semaglutide, the active ingredient in Wegovy** Novo has sued several compounders for allegedly selling unsafe, falsely advertised Wegovy \"knockoffs\" that violate its trademark rights, but the Hims lawsuit is its first U.S. patent case against a compounder** Up to last close, HIMS down 50% YTD(Reporting by Christy Santhosh)((Christy.Santhosh@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611979236","isCrawlerRequest":true}